港股異動 | 鉅子生物續升9% 上市3日累計漲幅達40% 市值超330億港元
格隆匯11月8日丨“膠原蛋白第一股”鉅子生物(2367.HK)午後一度拉昇漲至9%,上市3日累計漲幅達40%,最高報34.65港元再創新高價,總市值超330億港元。按零售額計算,鉅子生物是2021年中國第二大專業皮膚護理產品公司,同時從2019年起連續三年一直是中國最大的膠原蛋白專業皮膚護理產品公司。根據鉅子生物的規劃,其將於2023年上半年建成重組膠原蛋白髮酵車間產能21.25噸/年,產能擴大約20倍。國泰君安指,公司在港股上市,膠原蛋白性質優、應用廣,行業資本化加速下迎來發展機遇。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.